Rosetta Genomics Strikes Research Deal


Rosetta Genomics said Monday it has struck a research agreement with Sheba Medical Center at Tel HaShomer, Israel, to develop a microRNA-based signature to predict response to Nivolumab, an immunotherapy drug marketed by Bristol-Myers Squibb (BMY) as Opdivo, which is approved for the treatment of lung cancer patients.

The primary endpoint of the study is prediction of objective response rate as measured by tumor radiologic response to the immunotherapy. The secondary endpoint of the project is to predict survival benefit of advanced non-small cell lung cancer from immunotherapy as measured by overall survival (OS) and OS rate -12 and 24 months.

“Our goals for this collaboration with Sheba Medical dovetail with earlier work we conducted in partnership with large pharmaceutical companies that focused on establishing biomarkers to identify responders to certain immuno-oncology drugs,” Chief Scientific Officer Dganit Bar said.